Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Non-Current Assets (2016 - 2025)

Plus Therapeutics has reported Other Non-Current Assets over the past 16 years, most recently at $123000.0 for Q4 2025.

  • Quarterly Other Non-Current Assets rose 925.0% to $123000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123000.0 through Dec 2025, up 925.0% year-over-year, with the annual reading at $123000.0 for FY2025, 925.0% up from the prior year.
  • Other Non-Current Assets was $123000.0 for Q4 2025 at Plus Therapeutics, up from $45000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $123000.0 in Q4 2025 and troughed at $12000.0 in Q3 2022.
  • The 5-year median for Other Non-Current Assets is $16000.0 (2021), against an average of $27400.0.
  • Year-over-year, Other Non-Current Assets crashed 72.41% in 2021 and then surged 925.0% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $16000.0 in 2021, then fell by 25.0% to $12000.0 in 2022, then skyrocketed by 166.67% to $32000.0 in 2023, then plummeted by 62.5% to $12000.0 in 2024, then surged by 925.0% to $123000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Other Non-Current Assets are $123000.0 (Q4 2025), $45000.0 (Q3 2025), and $45000.0 (Q2 2025).